Proxima Research Secures $1.5M

Blueprints AI

Construction is the largest physical economy. Every building starts with a documentation set that has to obey gravity, code, and constructability. Blueprints AI is the industry world model for construction documentation. The platform generates code-compliant blueprints for real estate developers, design-build firms, and architecture firms, across residential and commercial projects. Teams can input floor plans, site information, and project requirements to generate full sets tailored to their specific standards.  The platform enables firms to dramatically increase their people-to-projects ratio and scale up or down with ease, compressing weeks of documentation into hours. Backed by NVIDIA Inception and Vercel AI Accelerator. Learn more at www.blueprints-ai.com.

Ecopliant Environmental, Inc.

Ecopliant Environmental, Inc. provides training, education, certification, renewal support, and consulting for environmental professionals working in erosion control, sediment control, stormwater compliance, construction site inspection, and SWPPP design and review. Core programs include CISEC, Certified Inspector of Sediment and Erosion Control, and CDSEC, Certified Designer of Sediment and Erosion Control. Through Ecopliant Institute and its certification programs, Ecopliant helps inspectors, designers, reviewers, contractors, consultants, and regulatory professionals strengthen their technical knowledge and demonstrate professional competency.

Nexio

The world of payments is a confusing and messy thing, but it doesn’t have to be. You just want to sell your product and services, or enable others to do just that. Where do you start? Where do you even begin? That is Nexio’s mission and passion. We strive to help companies of all sizes disentangle the complexity of payments, and plan for tomorrow. Simplifying complexity produces results. Since 2007, Nexio’s goal is turning payments complexities into growth and simplicity.

Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.

Aivora

Aivora is a next-generation crypto exchange, combining AI-driven innovation with secure, efficient trading for global users. Our team brings expertise from leading exchanges to deliver futures, spot, and emerging assets like RWA, GameFi, and DeFi... ? Stay connected: Twitter: @AivoraEX Telegram: t.me/AivoraEX